Physician Assistant Urgent Care
Resume:
Michael S. Biggin
Bowling Green, Ohio 43402
Home Phone 419-***-****
E-mail *******@*****.***
Hospital
Address: Toledo Children’s Hospital
Toledo, Ohio 43606
Business
Address: Toledo Children’s Hospital
2121 Hughes Dr., Suite 600 & 640
Toledo, Ohio 43606
WORK HISTORY: Physician Assistant-Pediatric Pulmonology
Pediatric Pulmonary Associates - Toledo, Ohio
November 2006 – Present
Responsible for seeing patients in the office and hospital, as well as assisting in bronchoscopies and following patients in the PICU
Physician Assistant- Nursery/neonatology
University hospitals Ahuja medical center
Beachwood, Ohio
August 2024 - present
Responsible for care of newborns in newborn nursery as well as level 2 special care nursery including attending hi-risk deliveries and procedures
Physician Assistant-Pediatric Urgent Care
Promedica Urgent Care for Kids – Perrysburg, Ohio
January 2020 – Present
Responsible for assessing and treating children in an urgent care setting
Lead Physician Assistant-Pediatrics
Pediatric Hospitalist Practice – Toledo, Ohio
Toledo Children’s Hospital
August 1997 – 2018
Responsible for interviewing potential employee candidates, evaluations, and scheduling work shifts
Responsible for assessing, admitting and following, pediatric patients on the hospital service. Perform consults in the E.D.
Physician Assistant
Pediatric Emergency Department – per diem
Dayton Childrens hospital
Dayton, Ohio 45404
Assess and treat patients as per Ohio law in a children’s Emergency Department fast track
October 2019-present
Physician Assistant
Pediatric Emergency Department – per diem
Toledo Children’s Hospital
Toledo, Ohio
January 2003-2017
Assess and treat patients as per Ohio law in a children’s Emergency Department
Senior Physician Assistant
Heartland Pediatric Associates
Sebring, Florida
June 1994 – August 1997
Patient care management on admitted patients at Florida Hospital Walker and Highlands Regional Medical Center as well as attending C-section and “High-Risk” deliveries.
Daily office schedule of patients, including treatment and examination of ill and routine scheduled care of pediatric patients ranging from newborn to late adolescence.
Assisted in general office management.
Experience with a broad spectrum of pediatric clinical cases.
Senior Physician Assistant
Geisinger Medical Center
NICU
Danville, Pennsylvania
September 1992 - May 1994
Perform examinations for admissions, pre and postoperative care for 23 bed Level III, NICU, and 14 bed NSCU
Assist in all “High-Risk” natural and C-section deliveries.
Responsible for: intubation; UA & UV line placements; chest tube insertion; ventricular, suprapubic, & spinal taps; I.V. lines: insertion care & maintenance; and surfactant administration.
Management of ventilators, oscillators, and high frequency jet ventilators.
Assist in orientation and instruction of PGYI-III Pediatric residents and P.A.s in the NICU.
Life flight retrieval personnel for retrieval of neonates to tertiary treatment center.
Hospital based instructor for Neonatal Resuscitation Course sponsored by the A.A.P.
Senior Physician Assistant
St. Vincent’s Medical Center of Richmond
Staten Island, New York
September 1989 - August 1992
Responsibilities equivalent to those described above.
Physician Assistant
Private Pediatric Practice - Warren, Ohio
September 1988 - September 1989; June 1982 - August 1987
Responsibilities equivalent to those described in previous position.
EDUCATION
Mt. Sinai Hospital - Hartford, Connecticut
Certificate in Pediatrics and Neonatology
Post Graduate Residency Training - September 1988
Post Graduate Clinical Training Facilities
September 1987 - September 1988
Mt. Sinai Hospital - Hartford, Connecticut
St. Francis Hospital - Hartford, Connecticut
Hartford Hospital - Hartford, Connecticut
Alderson-Broaddus College - Philippi, West Virginia
Bachelor of Science in Medical Science - May 1982
Pre-Graduate Training Facilities
May 1981 - May 1982
West Virginia University Medical Center - Morgantown, West Virginia
United Hospital Center - Clarksburg, West Virginia
VA Medical Center - Clarksburg, West Virginia
PROFESSIONAL ORGANIZATION & AFFILIATION
American Academy of Physicians Assistants
Ohio Association of Physician Assistants
Alderson-Broaddus College Alumni Association
RESEARCH TRIALS, SUB-INVESTIGATOR
A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Cross-Over Study to
Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsule in
Subjects with Pancreatic Exocrine Insufficiency due to Cystic Fibrosis (Solvay
Pharmaceuticals) 12/04/07 – 4/16/08.
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3
Study of Denufosol (INS37217) Inhalation Solution in Patients with Early Cystic Fibrosis
Lung Disease, 2/13/08-1/10/11.
Bayer 12429: A randomized, placebo-controlled, multi-center study to evaluate the safety and efficacy of ciprofloxacin (inhaled) compared to placebo in patients with Cystic Fibrosis, 4/24/08-2/23/11.
Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression, 4/24/08-2/23/11.
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study- DPM-CF-302, 5/29/08-1/19/11.
A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (AIR-CF4), 8/25/08-8/06/09.
Study 08-114: Open-Label Extension of Study 08-110 A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease, 2/09/09-3/07/11.
An Open Label, Multi-Center Study to Assess the Safety and tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than Seven Years of Age with Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis (S245.3.128), 4/15/09-9/01/09.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation (Vertex 102), 6/15/09-12/12/12
An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution versus Tobramycin Inhalation Solution in an Intermittent Aerosolized Antibiotic Regimen in Patients with Cystic Fibrosis, 10/05/09-8/26/10.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation (Vertex 104), 10/08/09-8/23/12.
Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) and Chronic Burkholderia Species Infection, 8/3/10-11/29/11.
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis (Vertex 105), 7/22/10-8/07/13.
(Mpex-207) A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MP-376 (Levofloxacin Inhalation Solution; Aeroquin™) in stable Cystic Fibrosis Patients, 2/04/11-7/26/12.
(Mpex-209) A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin ™) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients, 5/11-4/18/13.
(ALPINE) Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas aeruginsoa (PA) Aztreonam Lysine for Pseudomonas Infection Eradication, 9/12/11-8/07/13.
(CSP-00022) A Multi-Center Cystic Fibrosis Blood Sample Collection Study, 1/26/12-7/19/12. Hologic, Inc.
(VESTRI- SAS115358) A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma, 8/3/12-5/20/15.
(KaloBios) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of KB001-A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa, 1/4/13-2/4/15.
(VX12-809-104) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, 7/2013-7/28/14.
(GS-US-205-0170) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Subjects with Cystic Fibrosis, 4/13-4/23/15.
(MAP) Cystic Fibrosis Foundation Mutation Analysis Program, 3/01/13-present.
(VX12770-115) An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis, 4/26/13-7/23/15.
(VTPP Protocol: JSPP-12-01) A Point Prevalence Study to Evaluate the Prevalence of Antibiotics to Selected Porcine Viruses in Patients with Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors, 7/13-5/1/17.
(VX12-809-105) A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation, 11/13-5/19/16.
(GOAL) G551D Observational Study – Expanded to Additional Genotypes and Extended for Long Term Follow-up, 2/17/14-1/26/17.
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 meg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age with Persistent Asthma, 5/9/14-3/31/16
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Patients (DPM-CF-303), Sub-Investigator, 9/11/14-6/15/17.
A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 ug, 2 Actuations Twice Daily, Compared with Budesonide pMDI 80 ug, 2 Actuations Twice Daily, in Children Ages 6 to < 12 Years with Asthma, (D589GC00003), 1/22/15-5/25/16.
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients with Cystic Fibrosis (The IGNITE Study), 6/26/15-2/21/18.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients with Cystic Fibrosis (CF) (PS-G201), Sub-Investigator, 4/29/15-4/4/16.
A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive (VX14-661-109), Sub-Investigator, 8/27/15-11/22/17.
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (AN-EPI3331), Sub-Investigator, 10/15/15-3/21/18.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor (N91115-2CF-05) (SNO-6), Sub-Investigator, 11/15/15-1/19/17.
A Phase 3, Randomized, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (VX14-661-110), Sub-Investigator, 2/3/16-4/8/19 A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils (C38072-AS-30025), 1/8/16-10/17/16
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function (VX14-661-108), 4/27/16-4/24/17
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (AN-EPI3333) RESULT, 9/29/17-3/21/18.
A Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX14-661-111) 9/26/16-8/23/17
A Prospective Study to Assess the Pediatric Respiratory Syncytial Virus (RSV) Electronic Severity and Outcome Rating System (PRESORS) and Clinical Endpoints in Neeonates, Infants, and Children 36 Months of Age Hospitalized with RSV Infection, Protocol 64041575RSV0001, 8/18/17-11/21/19.
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients, (SAV005-04), 10/15/17-present.
A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in subjects with Cystic Fibrosis, (PTI-801-01), 9/28/17-present.
The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes, (CHEC-OB-17), 11/9/17-present.
A Multicenter, Human Factors validation study in Cystic Fibrosis patients aged 6 years and older to evaluate the user interface of TOBI® Podhaler™ (tobramycin inhalation powder) using placebo capsules, (CTBM100C2419), 3/29/18-4/17/19.
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination therapy in Subjects With Cystic Fibrosis Who are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (VX17-445-102), 6/7/18-6/18/19.
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F), (VX17-445-103), 7/2/18-2/20/19.
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation, (VX17-445-105), 9/6/18-present.
OPTION: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to assess the Safety and Efficacy of MS1819-SD in Patients with Exocrine Pancreatic with Insufficiency due to Cystic Fibrosis, Protocol: AZ-CF2001, 12/10/18-9/16/19.
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis, Protocol: VX18-561-101, 3/5/19-present.
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes), Protocol: VX18-445-104, 9/12/19-present.
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes), Protocol: VX18-445-110, 1/29/2020-present.
Contact this candidate